Medical News Today -
31 Oct 2013 11:00
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, has announced positive results for the 23 and 25 mm Porticoâ„¢ Transcatheter Aortic Heart Valves in the Portico Transfemoral CE Mark Trial (Portico TF CE Trial). Patients enrolled in the study experienced a significant improvement in valve function at 30 days. The preliminary findings indicate exceptional hemodynamic performance (the ability to maximize blood flow) and improvement in the severity of heart failure symptoms as mea...
Share this Article